Federal Court Rejects Veeva’s Attack on Medidata’s Theft of Trade Secret Claims
30 November 2018 - 12:30AM
Business Wire
The United States District Court for the Southern District of
New York has rejected Veeva’s motion to dismiss Medidata’s
complaint against Veeva for theft of trade secrets, the company
announced today.
“The Court’s decision allows us to continue with our effort to
hold Veeva accountable for its illegal and unethical
misappropriation of Medidata’s valuable proprietary information and
trade secrets,” said Erik Snider, senior director of corporate
communications at Medidata. “For close to 20 years, Medidata has
been a market leader through constant innovation, strong customer
relationships and a firm commitment to advancing science, all while
operating with integrity. Medidata recognizes and respects the
importance of intellectual property. We remain steadfast in the
protection of our trade secrets, which our employees have worked so
hard to create.”
In Monday’s decision:
- The Court rejected Veeva’s argument
that the complaint’s description of Medidata’s trade secrets was
insufficient.
- To the contrary, the Court stated that
the allegations were detailed and thorough, and the court upheld
each and every one of the claims that Medidata asserted against
Veeva.
Medidata alleges that Veeva willfully and deliberately stole the
company’s trade secrets, which include confidential and proprietary
information relating to the development, marketing and sale of
Medidata’s industry-leading technology solutions and services for
clinical research and trials.
In its complaint, Medidata explains how Veeva obtained
Medidata’s trade secrets and confidential information by
deliberately targeting Medidata’s employees and inducing them to
violate their contractual and other obligations to Medidata, rather
than competing fairly with Medidata on a level playing field.
Medidata’s complaint seeks injunctive relief and recovery of
damages that it has suffered as a result of Veeva’s theft and use
of its trade secrets.
About Medidata
Medidata (NASDAQ:MDSO) is leading the digital transformation of
life sciences, with the world's most used platform for clinical
development, commercial, and real-world data. Powered by artificial
intelligence and delivered by the #1 ranked industry experts, the
Intelligent Platform for Life Sciences helps pharmaceutical,
biotech, medical device companies, and academic researchers
accelerate value, minimize risk and optimize outcomes. Medidata
serves more than 1,000 customers and partners worldwide and
empowers more than 100,000 certified users every day to create hope
for millions of patients. Discover the future of life sciences:
www.mdsol.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181129005230/en/
Medidata SolutionsInvestors:Betsy Frank, +1
917-522-4620bfrank@mdsol.com
Media:Erik Snider, +1 646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Oct 2023 to Oct 2024